| 摘要 |
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment , prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in t he treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson~s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, th e treatment of obesity or eating disorders, as well as the treatment of asthma , constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
|
